Business Overview: Alto Neuroscience, Inc. (NYSE: ANRO)

---

Executive Summary

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company pioneering a biomarker-driven, precision-psychiatry approach to central nervous system (CNS) drug development. Founded by Stanford psychiatry researcher Dr. Amit Etkin, Alto's central thesis is that psychiatric diseases such as major depressive disorder (MDD), PTSD, and schizophrenia have historically been treated as monolithic diagnoses despite being biologically heterogeneous — meaning many CNS drugs fail in broad, unselected trial populations not because the drug doesn't work, but because it only works in a biologically distinct subset of patients.

Alto uses computational analysis of EEG, cognitive testing, and other objective biomarkers to identify which patient subpopulations are most likely to respond to a given mechanism, then designs trials that enroll (or stratify) around those biomarker-defined groups — an approach the company argues can rescue and de-risk CNS assets that would otherwise fail in traditional, biomarker-agnostic trials.

---

1. Core Business Model & How They Work

Alto operates the standard clinical-stage biotech value chain, but layers a proprietary patient-selection technology on top of it:

[ EEG / Biomarker Database ] ➡️ [ Computational Patient Stratification ] ➡️ [ Biomarker-Enriched Clinical Trials ] ➡️ [ Regulatory Approval in Defined Subpopulation ] ➡️ [ Companion Diagnostic-Guided Prescribing ]

Key Operational Drivers

1. Proprietary Biomarker Platform: Alto has built one of the larger prospective databases linking EEG/cognitive biomarkers to psychiatric drug response, sourced from its own trials and collaborations, which it uses to select which patients enroll in — and which drugs advance through — its pipeline.
2. Pipeline of Repositioned and Novel Assets: Alto's pipeline blends internally discovered molecules with assets licensed or acquired from larger pharma programs that previously underperformed in unselected populations, betting that biomarker stratification can identify where they actually work.
3. De-risked Trial Design: By enrolling biomarker-defined "responder-enriched" populations, Alto aims for smaller, faster, higher-probability-of-success trials than a traditional all-comers CNS study.

---

2. Pipeline & Products

---

3. Competitive Landscape

Competitors by Domain

CNS / Psychiatric Drug Development

• Key Competitors: Large pharma CNS franchises (Johnson & Johnson/Janssen, AbbVie, Otsuka/Lundbeck) with approved antidepressants and antipsychotics; newer precision-psychiatry and neuro-biotech peers (e.g., BrainStorm-style biomarker companies, Karuna-style novel-mechanism developers now part of Bristol Myers Squibb) pursuing differentiated mechanisms in overlapping indications.
• Dynamics: Alto is not competing head-to-head on a single molecule but on a development methodology — its bet is that biomarker-stratified trials will out-execute traditional biomarker-agnostic Phase 2/3 programs run by larger, better-funded competitors, which is a scientific and statistical wager as much as a commercial one.

Companion Diagnostics / Precision Medicine

• Key Competitors: Digital biomarker and EEG-analytics companies serving CNS trial sponsors broadly; Alto differentiates by using its platform exclusively to advance its own pipeline rather than selling biomarker services to third parties.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Proprietary biomarker dataset: A growing, proprietary library linking objective brain-activity and cognitive measures to drug response is difficult for competitors to replicate quickly and improves with every trial Alto runs.
• De-risked asset sourcing: Licensing molecules that already failed unselected trials (but had promising subgroup signals) can be capital-efficient versus discovering entirely novel chemistry.
• Founder-led scientific credibility: Deep academic grounding in computational psychiatry lends scientific credibility that can aid partnership and licensing discussions with larger pharma.

Strategic Risks & Vulnerabilities

1. Unproven Regulatory Path: The FDA has limited precedent for approving CNS drugs restricted to biomarker-defined psychiatric subpopulations, creating regulatory novelty risk.
   • Mitigation Strategy: Early and ongoing FDA engagement to align on biomarker-based trial design and potential companion diagnostic requirements.
2. Clinical Binary Risk: As with all clinical-stage biotech, any lead program's trial failure would be a significant setback.
3. Capital Intensity: Running multiple biomarker-enriched trials in parallel requires sustained financing.
   • Mitigation Strategy: Potential pharma partnerships or licensing deals to co-fund late-stage development.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

Alto Neuroscience is testing whether a data-driven, biomarker-first approach to psychiatric drug development can succeed where decades of biomarker-agnostic CNS trials have produced a long history of costly late-stage failures across the industry. Its proprietary EEG/cognitive biomarker platform is a genuine, hard-to-replicate asset if the underlying science holds up in pivotal trials.

The key long-term question is regulatory and clinical validation: whether Alto can demonstrate, in adequately powered pivotal studies, that its biomarker-selected patient populations produce cleaner, more reproducible efficacy signals than the industry's historical unselected-population approach — and whether the FDA will embrace biomarker-restricted psychiatric drug labels as a viable, scalable regulatory pathway.